Everything below concerns Reference standard. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
=== 21st century === Since 1999, Dairy Farm has continued to expand its footprint by acquiring supermarket and other retail operations in Taiwan, Malaysia, Singapore and Indonesia. Notably, it also acquired IKEA Hong Kong, Taiwan in 2002 and began Ikea's Indonesian operation in 2014. In May 2012, Dairy Farm bought a 50% stake in the Rustan Supercenters, Inc., the Rustan group's supermarket chain. 36% came from the Tantoco family and 14% from the Spinnaker group. Its holdings increased to 64% in 2015 and 100% in 2017. On March 23, 2018, the entire stake was sold to Robinsons Retail Holdings, Inc. through a stock swap, yielding Dairy Farm 18.25% of Robinsons Retail Holdings, Inc. stock. In 2018, therefore, Rustan Supercenters are fully acquired by Robinsons Retail Holdings the 20.00% of which is owned by Mulgrave Corporation and GCH Investments, wholly owned subsidiaries of Dairy Farm. As of June 2011, Dairy Farm is 78% owned by Jardine Matheson Holdings. In August 2021, Dairy Farm rebranded its trading name to DFI Retail Group. On 5 May 2022, the company subsequently changed its legal name to DFI Retail Group Holdings Limited, effectively phased out the Dairy Farm branding.
Humans use scorpions both practically, for medicine, food, and pets, and symbolically, whether as gods, to ward off harm, or to associate a product or business with the evident power of the small but deadly animal.
=== Toxic Death Rate === Unlike overall survival, which is based on death from any cause or the condition being treated, the toxic death rate picks up just the deaths that are directly attributable to the treatment itself. These rates are generally low to zero as clinical trials are typically halted when toxic deaths occur. Even with chemotherapy the overall rate is typically under a percent. However, the lack of systematic autopsies limits our understanding of deaths due to treatments.
The gross (macroscopic) appearance of the brain in Alzheimer's disease is variable. In many cases the cortical sulci are widened and the gyri are shrunken, but the degree of cortical atrophy varies. It can sometimes be difficult to discern, particularly in the very elderly. The areas most affected by atrophy are the medial temporal lobe including the hippocampal formation, the amygdala, the frontal lobe and the parietal lobe; the occipital lobe is relatively unaffected by atrophy. The volume of the ventricles increases in parallel with cortical shrinkage. Studies using MRI and PET have documented reductions in the size of specific brain regions in people with Alzheimer's disease as they progress from mild cognitive impairment to Alzheimer's disease, and in comparison with similar images from healthy older adults. These macroscopic changes in the brain are not specific to Alzheimer's and can occur in other disorders and to some extent in normal aging. At the microscopic level, the defining histopathologic characteristics of Alzheimer's disease are abundant amyloid plaques and neurofibrillary tangles in certain brain regions. Both of these abnormalities are clearly visible by microscopy, and amyloid imaging. In the early stages of disease, tangles are present mainly in the medial temporal lobe and plaques are present mainly in the neocortex, but as the disease progresses the lesions proliferate throughout much of the brain.
Sources: en.wikipedia.org
Manipulation of norepinephrine suggests it may actually play a role in creating a feeling of fatigue. Reboxetine, an NRI, decreased time to fatigue and increased subjective feelings of fatigue. This may be explained by a paradoxical decrease in adrenergic activity led by feedback mechanisms.
The dispersal of Indo-Europeans from a proposed homeland in the Pontic–Caspian steppe according to the Kurgan hypothesis is suggested to be linked to the spread of the R haplogroup subclade, R1a1, into Europe. R1a1 may also reflect the arrival of the Indo-Aryans into northern India. The Y-chromosomal lineage L could potentially reflect an earlier patrilingual dispersal of the proposed Elamo-Dravidian family emanating from a region in modern-day Iran. Austroasiatic speakers show a high frequency of the O2a haplogroup subclade. For example, Munda speakers in north and northeast India show high frequencies of O2a, not found in their regional neighbours who speak languages other than Austroasiatic, whilst their mtDNA haplogroups seem to be those frequent in their region independent of language affinity. A population genetic study of 23 Han Chinese populations has shown that the Han expansion southward during the sinification of what today is southern China was predominantly male-biased and is an uncontroversial example of the Father Tongue hypothesis. It has also been suggested that Bantu and other Niger-Congo languages correlate well with Y-chromosomal haplogroups. The spread of Afroasiatic languages has been linked to the expansion of E1b1b haplogroup.
=== Freedom of expression === A devout advocate for democracy, Bhutto Zardari has repeatedly denounced censorship and likened any forms of curbing media freedom to living under a dictatorship. He made a speech at the Karachi Press Club on World Press Freedom Day where he said, "An undeclared censorship is stifling the freedom of expression in Pakistan and journalists are coming under threat from state and non-state actors." He added, "Journalists and media persons as human rights defenders suffer the most when freedom of expression is stifled. After the right to life, the most important right is the right of expression and the freedom of association because all other rights cannot even be articulated without it." During the speech, he also criticized the Prevention of Electronic Crime Act 2016 and stated that it had been misapplied to stifle dissent.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.